ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES

被引：0
|
作者：
Wang, B. C. [1 ]
Nguyen, H. [2 ]
Furnback, W. [3 ]
Guzauskas, G. F. [1 ]
Hurd, J. [4 ]
Garrison, L. P. [5 ]
机构：
[1] Elysia Grp Ltd, Taipei, Taiwan
[2] AstraZeneca, Ft Washington, PA USA
[3] Elysia Grp LLC, New York, NY USA
[4] AstraZeneca, Columbus, PA USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1288
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB26
引用
收藏
页码：A201 / A201
页数：1
相关论文
共 50 条
  • [1] Estimating the long-term cost-effectiveness of exenatide in the United States: An adjunctive treatment for type 2 diabetes mellitus
    Minshall, Michael E.
    Oglesby, Alan K.
    Wintle, Matthew E.
    Valentine, William J.
    Roze, Stephane
    Palmer, Andrew J.
    VALUE IN HEALTH, 2008, 11 (01) : 22 - 33
  • [2] THE COST-EFFECTVENESE OF LIRAGLUTIDE VS EXENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UNITED STATES
    Ning, N.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A251 - A251
  • [3] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [4] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [5] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 67 - 77
  • [6] COST-UTILITY OF EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [7] Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine
    Secnik, K
    Hayes, C
    Matza, L
    Kim, S
    Oglesby, A
    Yurgin, N
    Brodows, R
    Malley, K
    VALUE IN HEALTH, 2005, 8 (06) : A155 - A156
  • [8] Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
    Braendle, M.
    Erny-Albrecht, K. M.
    Goodall, G.
    Spinas, G. A.
    Streit, P.
    Valentine, W. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (08) : 501 - 515
  • [9] Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
    Boye, Kristina Secnik
    Matza, Louis S.
    Oglesby, Alan
    Malley, Karen
    Kim, Sunny
    Hayes, Risa P.
    Brodows, Robert
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
  • [10] Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
    Kristina Secnik Boye
    Louis S Matza
    Alan Oglesby
    Karen Malley
    Sunny Kim
    Risa P Hayes
    Robert Brodows
    Health and Quality of Life Outcomes, 4
12345